Compile Data Set for Download or QSAR
maximum 50k data
Found 460 Enz. Inhib. hit(s) with all data for entry = 11501
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621094(US20230303563, Compound 40)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621094(US20230303563, Compound 40)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621095(6-(6-methoxyimidazo- [1,2-a]pyridin-3-yl)- N-((3S,...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621096((R)-N-(6-(6-methoxy- imidazo[1,2-a]pyridin- 3-yl)p...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621098(6-(6-(difluorometh- oxy)imidazo[1,2-a]- pyridin-3-...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621103(US20230303563, Compound 61)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621107(N-((3S,4S)-3-fluoro- piperidin-4-yl)-6-(7- methoxy...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621109(N-((3S,4S)-4-fluoro- pyrrolidin-3-yl)-6-(7- methox...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621111(1-(4-(3-(6-((4,4-difluoro- pyrrolidin-3-yl)amino)-...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621112(N-(4,4-difluoropyrrolidin- 3-yl)-6-(7-methoxy-6-(1...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621113(N-(4,4-difluoropyrrolidin- 3-yl)-6-(7-methoxy-6-(1...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621115(US20230303563, Compound 117)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621116(2-(3-(6-(((3S,4S)-4- fluoropyrrolidin-3- yl)amino)...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621116(2-(3-(6-(((3S,4S)-4- fluoropyrrolidin-3- yl)amino)...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621121(6-(6-cyclopropylimidazo[1,2- a]pyridin-3-yl)-N-((3...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621126(6-(6- (difluoromethyl)imidazo[1,2- a]pyridin-3-yl)...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621127(6-(6- (difluoromethyl)imidazo[1,2- a]pyridin-3-yl)...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621130(N-(6-(6- (difluoromethyl)imidazo[1,2- a]pyridin-3-...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621131(N-(6-(6- (difluoromethyl)imidazo[1,2- a]pyridin-3-...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621134(N-((3S,4S)-4- fluoropiperidin-3-yl)-6-(7- isopropo...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621135(4-fluoro-N-((3S,4S)-4- fluoropyrrolidin-3-yl)-6- (...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621137(3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621137(3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621138(N-((3S,4S)-4- fluoropiperidin-3-yl)-4-(7- isopropo...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621140(US20230303563, Compound 215)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621141(US20230303563, Compound 216)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621141(US20230303563, Compound 216)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621142(Fast-eluting diastereomer: 1,1,1-trifluoro-2-(3-(6...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621142(Fast-eluting diastereomer: 1,1,1-trifluoro-2-(3-(6...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621144(6-(6-chloro-7- isopropoxyimidazo[1,2- a]pyridin-3-...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621147(US20230303563, Compound 224)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621148(US20230303563, Compound 226)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621149(US20230303563, Compound 231)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621149(US20230303563, Compound 231)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621150(2-(3-(3,5-difluoro-6- (((3S,4S)-4- fluoropiperidin...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621150(2-(3-(3,5-difluoro-6- (((3S,4S)-4- fluoropiperidin...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621151(Fast-eluting diastereomer: 1,1,1-trifluoro-2-(3-(6...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621151(Fast-eluting diastereomer: 1,1,1-trifluoro-2-(3-(6...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621153(Fast-eluting diastereomer: 1,1,1-trifluoro-2-(3-(6...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621153(Fast-eluting diastereomer: 1,1,1-trifluoro-2-(3-(6...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621153(Fast-eluting diastereomer: 1,1,1-trifluoro-2-(3-(6...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621153(Fast-eluting diastereomer: 1,1,1-trifluoro-2-(3-(6...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621155(Fast-eluting diastereomer: 2- (3-(6-((R)-5- azaspi...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621155(Fast-eluting diastereomer: 2- (3-(6-((R)-5- azaspi...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621155(Fast-eluting diastereomer: 2- (3-(6-((R)-5- azaspi...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621158(US20230303563, Compound 257)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621159(6-(7-(1H-imidazol-2- yl)imidazo[1,2-a]pyridin-3- y...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621160(6-(7-(2,2- difluoroethoxy)imidazo[1,2- a]pyridin-3...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM621160(6-(7-(2,2- difluoroethoxy)imidazo[1,2- a]pyridin-3...)
Affinity DataIC50: <0.5nMAssay Description:Table 32: The reagent used was as follows: Base Reaction buffer; 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.016 Brij35, 0.02 mg/ml BSA, 0.1 mM N...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 460 total ) | Next | Last >>
Jump to: